Zurcher Kantonalbank Zurich Cantonalbank Buys 168,975 Shares of Moderna, Inc. (NASDAQ:MRNA)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 107.1% in the fourth quarter, Holdings Channel reports. The firm owned 326,749 shares of the company’s stock after purchasing an additional 168,975 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Moderna were worth $13,586,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of Moderna during the 4th quarter worth approximately $37,000. Venturi Wealth Management LLC increased its stake in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after purchasing an additional 388 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on MRNA. Wolfe Research assumed coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Leerink Partners decreased their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Morgan Stanley decreased their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Finally, The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $60.63.

Moderna Trading Up 3.7 %

Shares of MRNA stock opened at $35.01 on Thursday. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The stock has a market cap of $13.51 billion, a price-to-earnings ratio of -3.77 and a beta of 1.86. The stock has a 50-day moving average of $36.25 and a 200-day moving average of $48.01.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.